期刊文献+

成骨生长肽羧基端片段衍生物H86A对去卵巢大鼠骨计量学的影响

Effects of OGP derivate H86A on Bone Metrology in Ovariectomized Rats
原文传递
导出
摘要 目的探讨成骨生长肽羧基端片段及其衍生物H86A对去卵巢(OVX)骨质疏松大鼠骨计量学的影响。方法将32只3月龄SD雌性大鼠分为4组,1~3组行OVX手术,1、2组术后分别给予高低剂量的H86A,3组给予安慰剂,4组为假手术组(SHAM)。12周后处死动物,分离左侧胫骨,制成不脱钙骨切片,检测并分析骨计量学有关指标。结果H86A高剂量组(H86AH)与去卵巢给安慰剂组(OVX)比较,OV/BV减少(P<0.01),其他指标无统计意义;与SHAM组比较,BV/TV、Tb.Th、Tb.N减少(P<0.01),Tb.Sp、OV/BV增加(P<0.01),其他指标无统计学意义(P>0.05)。H86A低剂量(H86AL)组与OVX组比较,BV/TV增加(P<0.05),OV/BV减少(P<0.01),sLS/BS、Ms/BS增加(P<0.01),与SHAM组比较,BV/TV、Tb.Th、Tb.N减少(P<0.01),Tb.Sp、OV/BV增加(P<0.01),sLS/BS、MS/BS增加(P<0.01),其他指标无统计学意义。结论成骨生长肽羧基端片段及其衍生物可以提高骨量,改善骨组织的微结构,改善骨质疏松的骨质量。 Objective To investigate the effects of OGP (10-14) and its derivate H86A on bone metrology in rats with ovarieetomy-reduced osteoporosis. Methods Thirty-two female Sprague-Dawley rats, three months old, were randomly divided into 4 groups. Rats in groups 1 to 3 were bilaterally ovarieetomized(OVX) and the others in group 4 were sham-operated. After the operation, rats in group 1 and group 2 were received derivate of OGP(10-14) H86A daily at different concentration. Group 3 were given placebo. Rats were killed after 12 weeks. Left tibias were disconnected and made into non-decalcified bone slice, and then they were detected and analyzed on indexes which were relative with bone metrology. Results Compared with Group 3, no other indexes except OV/BV was obviously different in rats with high dose H86A (P〈0.01). Compared with group 4, BV/TV, Tb.Th and Tb.N were diminished (P〈0.01), Tb.Sp and OV/BV were raised (P〈0.01) in rats with high dose H86A, but no statistically significant in other indexes. Compared with rats in group 3, rats with low dose H86A had increased BV/TV (P〈0.05), sLS/BS, Ms/BS (P〈0.01), and decreased OV/BV (P〈0.01); but BV/ TV, Tb.Th, Th.N were decreased (P〈0.01) and Tb.Sp, OV/BV, sLS/BS, MS/BS were increased compared to rats in SHAM. Conclusion OGP (10-14) and its derivate can increase bone mass, improve microstruetural of bone, and enhance bone quality of rats with osteoporosis.
出处 《中国慢性病预防与控制》 CAS 北大核心 2009年第2期137-138,141,共3页 Chinese Journal of Prevention and Control of Chronic Diseases
基金 国家自然科学基金资助项目(30271530)
关键词 成骨生长肽 衍生物 骨质疏松 骨计量学 Primary osteoporosis Community intervention Intervention pattern Effectiveness
  • 相关文献

参考文献7

  • 1陆再英,钟南山.内科学[M].第7版.北京:人民卫生出版社.2007:835-840.
  • 2Mattii L, Battolla B, Moscato S, et al. The small peptide OGP (10-14)acts through Src kinases and RhoA pathways in Mo-7e cells: morphologic and immunologic evaluation [J]. Med Sci Monit, 2008, 4: 103- 108.
  • 3Chen YC, Bab I, Mansur N, et al.Structure-bioactivity of C-terminal pentapeptide of osteogenic growth peptide [OGP (10-14)] [J]. J Pept Res, 2000, 56: 147-156.
  • 4Berger C, Langsetmo L, Joseph Let al. Change in bone mineral density as a function of age in women and men and association with the use of antiresorptive agents[J]. CMAJ, 2008, 178: 1660-1668.
  • 5Woo JT, Kawatani M, Kato M, et al. Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts[J). Proc Natl Acad Sci, 2006, 3: 4729-4734.
  • 6Burt-Pichat B, Lafage-Proust MH, Duboeuf F, et al. Dramatic decrease of innervation density in bone after ovariectomy [J]. Endocrinology, 2005,46:503-510.
  • 7施德源,俞超,陈统一,崔大敷,陈中伟.成骨生长肽促进大鼠骨量增加的作用[J].上海医科大学学报,1999,26(3):187-190. 被引量:24

共引文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部